Diclofenac‐induced pseudoporphyria; an under‐recognized condition? | Zendy

Turnbull N. | Zendy; Callan M. | Zendy; Staughton R. C. D. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Diclofenac‐induced pseudoporphyria; an under‐recognized condition?

Author(s) -

Turnbull N.,

Callan M.,

Staughton R. C. D.

Publication year - 2014

Publication title -

clinical and experimental dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.587

H-Index - 78

eISSN - 1365-2230

pISSN - 0307-6938

DOI - 10.1111/ced.12313

Subject(s) - diclofenac , porphyria cutanea tarda , medicine , dermatology , nonsteroidal , porphyria , naproxen , psoriasis , pathology , pharmacology , alternative medicine

Summary Pseudoporphyria is a photodistributed bullous disorder that is clinically and histologically similar to porphyria cutanea tarda ( PCT ), but without abnormal porphyrin biochemistry. Renal failure, dialysis, excessive ultraviolet A and medications, particularly nonsteroidal anti‐inflammatory drugs ( NSAID s), have been associated with pseudoporphyria. We report a case of diclofenac‐induced pseudoporphyria in a man with psoriatic arthritis. To our knowledge, this is only the second reported case of pseudoporphyria associated with diclofenac. Diclofenac has hitherto been considered by many dermatologists as a safe alternative in NSAID ‐induced pseudoporphyria.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research